Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
30 hedge funds and large institutions have $31.1M invested in Aptose Biosciences, Inc. in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.
370% more capital invested
Capital invested by funds: $6.62M → $31.1M (+$24.5M)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
36% more funds holding
Funds holding: 22 → 30 (+8)
96% less call options, than puts
Call options by funds: $5K | Put options by funds: $130K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.85M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.5M |
| 3 |
Man Group
London,
United Kingdom
|
+$3.03M |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
+$1.61M |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$448K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$129K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66K |
| 3 |
NFG
Noven Financial Group
Denver,
Colorado
|
-$37K |
| 4 |
Jane Street
New York
|
-$35K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$25K |
APTO Hedge Fund Activity: Q2 2019 in Review
30 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2019, worth a combined $31.1M — up 370% from $6.62M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new APTO positions and 4 closed out — a net gain of 8 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $6.85M. The largest seller was Virtu Financial, cutting an estimated $129K.
- 30 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2019, up from 22 in Q1 2019.
- Funds reported $31.1M of Aptose Biosciences, Inc. stock for Q2 2019, up 370% quarter-over-quarter.
- 12 funds opened new Aptose Biosciences, Inc. positions in Q2 2019 and 4 closed out, a net change of +8 holders.
- The largest Aptose Biosciences, Inc. buyer in Q2 2019 was Nantahala Capital Management, an estimated $6.85M added.
- The largest Aptose Biosciences, Inc. seller in Q2 2019 was Virtu Financial, an estimated $129K sold.
Based on aggregated 13F filings for Q2 2019.